Griffin's Citadel Adds AbbVie and Abbott as Healthcare Bid Firms

Billionaire hedge fund manager Ken Griffin added to positions in AbbVie and Abbott, two large-cap healthcare names that traded at $264.52 and $116.67 respectively as of 20:00 GMT on Aug. 24, 2026.

Ken Griffin, the founder of Citadel and one of the most closely watched allocators in the hedge fund world, has added to positions in two of the largest names in American healthcare: AbbVie and Abbott. The disclosure lands at a moment when the broad market is drifting rather than driving, and when defensive cash generators are quietly doing better than the crowded growth trade.

AbbVie (NYSE: ABBV) changed hands at $264.52 as of 20:00 GMT on Aug. 24, 2026, down 0.17% on the session from a previous close of $264.96, inside a day range of $262.07 to $266.04. Abbott (NYSE: ABT) sat at $116.67, up 0.03%, against a prior close of $116.64 and a range of $115.82 to $117.34. Neither stock moved much. That, in itself, is part of the story.

Two flat tapes inside a split market

The backdrop matters more than the individual ticks. The Nasdaq 100 proxy QQQ fell 1.00% to $706.32 on the day, the S&P 500 tracker SPY slipped 0.29% to $763.47, while the Dow 30 fund DIA rose 0.27% to $533.65. That is the shape of a rotation: money leaving high-multiple technology and finding its way into older, cash-heavy industrials and healthcare names that populate the Dow.

Against a Nasdaq down a full percentage point, AbbVie's 0.17% dip and Abbott's fractional gain both count as relative outperformance. Neither is a dramatic result. But investors who have spent 2026 watching semiconductor names swing several percent in a session will recognise the appeal of a stock whose entire day's trading covered a range of a few dollars.

What a Griffin position does and does not tell you

Citadel is a multistrategy firm. Its equity book is enormous, it is run by many teams, and a large share of it exists to hedge, to arbitrage, or to express a view that has nothing to do with a simple bullish call on a company's next five years. A position appearing in a quarterly filing is a snapshot of what was held on one date in the past, not a live signal, and it may already have been trimmed or reversed by the time the public sees it.

That is the standing caveat on all 13F-following. The more useful reading is directional and thematic: one of the most sophisticated risk operations on Wall Street found room for more large-cap pharma and medical devices. Retail investors cannot replicate Citadel's hedges, its leverage, or its holding period. They can, however, ask the same question the position implies — whether established healthcare businesses are being priced sensibly relative to what they still have ahead of them.

The case laid out by Motley Fool rests on exactly that combination: mature, established operations paired with credible long-term growth avenues. It is a description that fits both companies, though for different reasons.

Different businesses wearing the same label

Grouping AbbVie and Abbott together as "healthcare" obscures how differently they earn money. AbbVie is a pharmaceutical developer. Its economics are patent economics — a small number of therapies carry an outsized share of profit, protection eventually lapses, and management's core job is refilling the pipeline before the cliff arrives. The upside is exceptional margins while exclusivity holds. The risk is concentration and the binary nature of clinical and regulatory outcomes.

Abbott is closer to a diversified medical products company, spanning devices, diagnostics, nutrition and established pharmaceuticals. Revenue is spread across many product lines and geographies, and demand is driven by procedure volumes, hospital budgets and chronic disease management rather than by a handful of blockbuster molecules. That produces a smoother, less spectacular earnings profile, with growth tied to installed bases and consumable resupply.

Owning both is therefore not a doubled-up bet. It is a barbell inside one sector: patent-driven pharmaceutical profitability on one side, recurring device and diagnostics revenue on the other. For a portfolio built to survive a variety of macro outcomes, that pairing has an internal logic that a pair of pharma names would not.

The valuation question retail investors actually face

Neither stock is a discovery. Both are widely held, heavily covered and priced accordingly. Buying either today is a judgment that the growth still to come justifies a multiple the market has already assigned to a well-understood franchise — not a bet that anyone has overlooked something.

Practical questions to work through before acting on someone else's filing:

• Pipeline coverage at AbbVie. How much of current profit is exposed to patent expiry over the next several years, and what is credibly positioned to replace it?
• Volume sensitivity at Abbott. Device and diagnostics revenue tracks healthcare utilisation. Weak procedure volumes or hospital capital budgets show up in results with a lag.
• Dividend durability. Both are long-standing income names. The question is not whether the payout exists but whether free cash flow covers it comfortably through a bad year.
• Policy exposure. Drug pricing and reimbursement politics touch pharmaceutical earnings directly and device makers indirectly.
• Your entry versus Griffin's. A filing shows what was bought, not at what price, and rarely on the day you read it.

What to watch from here

The near-term test for these two is whether the rotation visible on Aug. 24 — Dow up, Nasdaq down a full percent — persists or reverses. Defensive healthcare tends to earn its keep precisely when growth stocks stop working, and a stretch of that kind would validate the positioning regardless of company-specific news.

Beyond the tape, the substantive catalysts are the ordinary ones: quarterly results, pipeline readouts and regulatory decisions at AbbVie, and segment growth rates plus margin trends at Abbott. Subsequent Citadel filings will eventually show whether the positions were held, added to or closed out. That will arrive months after the fact, which is the point worth remembering about this entire genre of news: by the time a billionaire's trade is public, it is history. The businesses underneath it are not.

Key facts

• ABBV price: $264.52, -0.17% as of 20:00 GMT Aug. 24, 2026
• ABT price: $116.67, +0.03% as of 20:00 GMT Aug. 24, 2026
• Market backdrop: QQQ -1.00%, SPY -0.29%, DIA +0.27% on the day
• Investor: Ken Griffin, founder of Citadel, added to both positions

Frequently asked questions

What did Ken Griffin buy?

Griffin, the billionaire founder of hedge fund Citadel, added to positions in AbbVie and Abbott, two large-capitalisation American healthcare companies. AbbVie is a pharmaceutical developer; Abbott spans medical devices, diagnostics, nutrition and established pharmaceuticals. The disclosure does not reveal the price paid or whether the positions are still held today.

How did the two stocks trade on the day?

As of 20:00 GMT on Aug. 24, 2026, AbbVie traded at $264.52, down 0.17% from its previous close of $264.96, within a range of $262.07 to $266.04. Abbott traded at $116.67, up 0.03% from $116.64, ranging between $115.82 and $117.34. Both were quiet sessions.

Why does a 13F filing come with caveats?

A quarterly institutional holdings filing shows what a manager held on a past date, not what they hold now. Multistrategy firms like Citadel run hedges, arbitrage and short-horizon trades alongside long-term convictions, so a single equity line may not represent a bullish view at all. Positions can be closed before the public sees them.

How are AbbVie and Abbott different as businesses?

AbbVie's profits depend on patent-protected pharmaceutical therapies, giving high margins while exclusivity lasts but exposure to patent cliffs and clinical outcomes. Abbott earns across devices, diagnostics, nutrition and established drugs, producing steadier, more diversified revenue tied to procedure volumes and consumable resupply rather than a few blockbuster molecules.

What was the wider market doing that day?

Markets were split. The Nasdaq 100 proxy QQQ fell 1.00% to $706.32 and the S&P 500 tracker SPY slipped 0.29% to $763.47, while the Dow 30 fund DIA gained 0.27% to $533.65. That pattern suggests money rotating out of high-multiple technology into older, cash-generative names.

What should investors watch next on these two names?

For AbbVie, the key items are pipeline readouts, regulatory decisions and how much current profit is exposed to upcoming patent expiries. For Abbott, watch segment growth rates, margin trends and healthcare utilisation, which drives device and diagnostics demand. Broader drug pricing and reimbursement policy affects both, directly and indirectly.

Sources

• Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead. — Motley Fool

Photo: Beelith USA · Pexels Licence — source